Why Deciphera Pharmaceuticals Stock Is Nosediving

Deciphera Pharmaceuticals Inc DCPH shares are trading lower by 10.48% to $18.45 Thursday morning after the company announced a $125 million proposed public offering of common stock.

In addition, Deciphera intends to grant the underwriters a 30-day option to purchase up to an additional $18,750,000 of shares of common stock offered in the public offering.

Deciphera says the company intends to use the net proceeds from the offering to fund its planned Phase 3 INSIGHT study of QINLOCK® versus sunitinib in second-line GIST patients with mutations in KIT exon 11 and 17/18 only, among many other strategies.

See Also: Why Allstate Stock Is Hitting The Brakes Today

According to data from Benzinga Pro, DCPH has a 52-week high of $22.76 and a 52-week low of $6.51.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: NewsOfferingsSmall Capwhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!